This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

Claims 1 to 25 ***(cancelled)***

26. ***(currently amended)*** A method of treating a subject suffering from a condition selected from the group consisting of ~~neurodegenerative disease~~ **Alzheimer's disease**, ~~eating disorders~~ **appetite control**, disorders of thermoregulation, **and** sleep dysfunction ~~and sexual dysfunction~~, comprising the step of:

providing to the subject suffering from said condition, a therapeutically effective amount of a compound of formula I



8

(I)

wherein

R^1 is a straight-chained alkyl of 1 to 6 carbon atoms, or a branched chain alkyl of 3 to 8 carbon atoms; and

R^2 is phenyl, naphthyl, anthracyl, phenanthryl, pyridyl, pyrimidyl, triazinyl, furyl, pyrrolyl, pyrazolyl, indolyl, imidazolyl, benzofuryl, benzothienyl, oxazolyl, or thiazolyl each optionally substituted with 0 to 3 substituents selected from straight-chain alkyl of 1 to 6 carbon atoms, branched-chain alkyl of 3 to 8 carbon atoms, alkoxy of 1 to 6 carbon atoms, mono- or dialkylamino of 1 to 6 carbon atoms, nitro, halo, amino, cyano, trifluoromethyl, trifluoromethoxy and hydroxy;

or a pharmaceutically acceptable salt thereof.

Claims 27 to 32 ***(cancelled)***

33. ***(previously presented)*** A method according to claim 26, wherein said subject is a human.

34. ***(previously presented)*** A method according to claim 26, wherein R^1 is a straight-chained alkyl of 1 to 3 carbon atoms, or a branched chain alkyl of 3 to 6 carbon atoms.

35. ***(previously presented)*** A method according to claim 26, wherein R^1 is a straight-chained alkyl of 1 or 2 carbon atoms.

36. ***(previously presented)*** A method according to claim 26, wherein R^2 is phenyl, naphthyl, pyridyl, pyrimidyl, furyl, pyrrolyl, pyrazolyl, indolyl, imidazolyl, benzofuryl, or benzothienyl; each optionally substituted with 1 to 3 substituents the same or different selected from straight-chain alkyl of 1 to 3 carbon atoms, branched-chain alkyl of 3 to 6 carbon atoms, alkoxy of 1 to 3 carbon atoms, mono- or di-alkylamino in which each alkyl group has 1 to 3 carbon atoms, nitro, amino, cyano, halogen, trifluoromethyl, trifluoromethoxy, and hydroxy.

37. ***(previously presented)*** A method according to claim 26, wherein R^2 is phenyl, naphthyl, pyridyl, pyrrolyl, indolyl, or benzothienyl; each optionally substituted with 1 to 3 substituents the same or different selected from nitro, amino, cyano, halogen, trifluoromethyl, trifluoromethoxy, and hydroxy.

38. ***(previously presented)*** A method according to claim 26, wherein R^2 is trifluoromethylphenyl or methoxyphenyl.

39. ***(previously presented)*** A method according to claim 26, wherein the R^1O substituent is bonded to the 1,4-benzodioxan nucleus at the 8 position.

40. ***(previously presented)*** A method according to claim 26, wherein R^1 is a straight-chained alkyl of 1 to 3 carbon atoms, or a branched chain alkyl of 3 to 6 carbon atoms and R^2 is phenyl, naphthyl, pyridyl, pyrimidyl, furyl, pyrrolyl, pyrazolyl, indolyl, imidazolyl, benzofuryl, or benzothienyl; each optionally substituted with 0 to 3 substituents selected from straight-chain alkyl of 1 to 3 carbon atoms, branched-chain alkyl of 3 to 6 carbon atoms, alkoxy of 1 to 3 carbon atoms, mono- or di-alkylamino in which each alkyl group has 1 to 3 carbon atoms, halogen, trifluoromethyl, trifluoromethoxy, and hydroxy.

41. ***(previously presented)*** A method according to claim 26, wherein R^1 is a straight-chained alkyl of 1 or 2 carbon atoms, and R^2 is phenyl, naphthyl, pyridyl, pyrrolyl, indolyl, or benzothienyl; each optionally substituted with a 0 to 3 substituents selected from nitro, amino, cyano, halogen, trifluoromethyl, trifluoromethoxy, and hydroxy.

42. ***(previously presented)*** A method according to claim 26, wherein R^1 is a straight chain alkyl of 1 or 2 carbon atoms and R^2 is trifluoromethylphenyl or methoxyphenyl.

43. ***(previously presented)*** A method according to claim 26, wherein said compound is (*S*)-8-(8-ethoxy-2,3-dihydrobenzo-[1,4]dioxin-2-ylmethyl)-3-naphthalen-2-yl-8-aza-bicyclo[3.2.1] octan-3-ol or a pharmaceutically acceptable salt thereof.

43. ***(previously presented)*** A method according to claim 26, wherein said compound is (*S*)-8-(8-ethoxy-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-3-phenyl-8-aza-bicyclo[3.2.1]octan-3-ol or a pharmaceutically acceptable salt thereof.

44. ***(previously presented)*** A method according to claim 26, wherein said compound is (*S*)-3-benzo[b]thiophen-3-yl-8-(8-ethoxy-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-8-aza-bicyclo[3.2.1]octan-3-ol or a pharmaceutically acceptable salt thereof.

45. ***(previously presented)*** A method according to claim 26, wherein said compound is 8-{[(2S)-8-ethoxy-2,3-dihydrobenzo-[1,4]dioxin-2-yl]methyl)-3-pyridin-2-yl-8-aza-bicyclo [3.2.1]octan-3-ol or a pharmaceutically acceptable salt thereof.

46. ***(previously presented)*** A method according to claim 26, wherein said compound is 8-{[(2S)-8-ethoxy-2,3-dihydrobenzo-[1,4]dioxin-2-yl]methyl)-3-(3-trifluoromethyl-phenyl)-8-aza-bicyclo[3.2.1]octan-3-ol or a pharmaceutically acceptable salt thereof.

47. ***(previously presented)*** A method according to claim 26, wherein said compound is 8-{[(2S)-8-methoxy-2,3-dihydro-1,4-benzodioxin-2-yl]methyl}-3-(2-methoxyphenyl)-8-azabicyclo[3.2.1]octan-3-ol or a pharmaceutically acceptable salt thereof.

48. ***(previously presented)*** A method according to claim 26, wherein said compound is 8-{[(2S)-8-methoxy-2,3-dihydro-1,4-benzodioxin-2-yl]methyl}-3-[3-(trifluoromethyl)phenyl]-8-azabicyclo[3.2.1]octan-3-ol or a pharmaceutically acceptable salt thereof.

49. ***(previously presented)*** A method according to claim 26, wherein said compound is 8-{[(2S)-8-methoxy-2,3-dihydro-1,4-benzodioxin-2-yl]methyl}-3-(2-pyridinyl)-8-azabicyclo[3.2.1]octan-3-ol or a pharmaceutically acceptable salt thereof.

50. ***(previously presented)*** A method according to claim 26, wherein said compound is 3-(1-benzothien-3-yl)-8-{[(2S)-8-methoxy-2,3-dihydro-1,4-benzodioxin-2-yl]methyl}-8-azabicyclo[3.2.1]octan-3-ol or a pharmaceutically acceptable salt thereof.

51. ***(previously presented)*** A method according to claim 26, wherein said compound is 8-{[(2S)-8-methoxy-2,3-dihydro-1,4-benzodioxin-2-yl]methyl}-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol or a pharmaceutically acceptable salt thereof.

52. ***(previously presented)*** A method according to claim 26, wherein said compound is 3-((2S)-8-methoxy-2,3-dihydrobenzo- [1,4]dioxin-2-ylmethyl)-8-naphthalen-2-yl-3-aza-bicyclo[3.2.1]octan-8-ol or a pharmaceutically acceptable salt thereof.